Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

545 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tissue-based immune monitoring II: multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinoma.
Hagemann AR, Hagemann IS, Cadungog M, Hwang WT, Patel P, Lal P, Hammond R, Gimotty PA, Chu CS, Rubin SC, Birrer MJ, Powell DJ Jr, Feldman MD, Coukos G. Hagemann AR, et al. Among authors: lal p. Cancer Biol Ther. 2011 Aug 15;12(4):367-77. doi: 10.4161/cbt.12.4.16908. Epub 2011 Aug 15. Cancer Biol Ther. 2011. PMID: 21785280 Free PMC article.
An active learning approach for rapid characterization of endothelial cells in human tumors.
Padmanabhan RK, Somasundar VH, Griffith SD, Zhu J, Samoyedny D, Tan KS, Hu J, Liao X, Carin L, Yoon SS, Flaherty KT, Dipaola RS, Heitjan DF, Lal P, Feldman MD, Roysam B, Lee WM. Padmanabhan RK, et al. Among authors: lal p. PLoS One. 2014 Mar 6;9(3):e90495. doi: 10.1371/journal.pone.0090495. eCollection 2014. PLoS One. 2014. PMID: 24603893 Free PMC article.
CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.
DeMichele A, Clark AS, Tan KS, Heitjan DF, Gramlich K, Gallagher M, Lal P, Feldman M, Zhang P, Colameco C, Lewis D, Langer M, Goodman N, Domchek S, Gogineni K, Rosen M, Fox K, O'Dwyer P. DeMichele A, et al. Among authors: lal p. Clin Cancer Res. 2015 Mar 1;21(5):995-1001. doi: 10.1158/1078-0432.CCR-14-2258. Epub 2014 Dec 11. Clin Cancer Res. 2015. PMID: 25501126 Clinical Trial.
Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer.
Yamoah K, Johnson MH, Choeurng V, Faisal FA, Yousefi K, Haddad Z, Ross AE, Alshalafa M, Den R, Lal P, Feldman M, Dicker AP, Klein EA, Davicioni E, Rebbeck TR, Schaeffer EM. Yamoah K, et al. Among authors: lal p. J Clin Oncol. 2015 Sep 1;33(25):2789-96. doi: 10.1200/JCO.2014.59.8912. Epub 2015 Jul 20. J Clin Oncol. 2015. PMID: 26195723 Free PMC article.
COX-2 mediates pro-tumorigenic effects of PKCε in prostate cancer.
Garg R, Blando JM, Perez CJ, Lal P, Feldman MD, Smyth EM, Ricciotti E, Grosser T, Benavides F, Kazanietz MG. Garg R, et al. Among authors: lal p. Oncogene. 2018 Aug;37(34):4735-4749. doi: 10.1038/s41388-018-0318-9. Epub 2018 May 16. Oncogene. 2018. PMID: 29765153 Free PMC article.
545 results